Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

QT interval prolongation and cardiac risk assessment for novel drugs.

Current opinion in investigational drugs (London, England : 2000) - 1 Mar 2003

Picard Sandra, Lacroix Pierre

Abstract excerpt

Fatal cardiac arrhythmias, known as torsades de pointes, can occur with a wide variety of medicinal drugs and are associated with prolongation of the QT interval. This review critically evaluates the major strategies for assessing QT prolongation risk: ion channel studies, in vitro cardiac electrophysiology, and in vivo cardiac electrophysiology and hemodynamics. Disease- or drug-induced QT prolongation is mainly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug-Related Side Effects and Adverse Reactions
Share to ERG1 Potassium Channel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ether-A-Go-Go Potassium Channels

Share to KCNQ Potassium Channels

Share to KCNQ1 Potassium Channel

Share to Potassium Channels, Voltage-Gated

Share to Torsades de Pointes

Share to Transcriptional Regulator ERG

Source

Identifiers

PMID: 12735231

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

QT interval prolongation and cardiac risk assessment for novel drugs.PMID 12735231Read ↗

Acquired QT interval prolongation and HERG: implications for drug discovery and development.Semantic proximity Read ↗

Molecular predictors of drug-induced prolongation of the QT interval.Semantic proximity Read ↗

Drug-induced torsades de pointes: the evolving role of pharmacogenetics.Semantic proximity Read ↗

Drug‐ and non‐drug‐associated QT interval prolongationSemantic proximity Read ↗

[HERG K+ channel, the target of anti-arrhythmias drugs].Semantic proximity Read ↗

Dangerous and life-threatening drugs - practical lessons from the long QT syndrome.Semantic proximity Read ↗

Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.Semantic proximity Read ↗

Pharmacology of cardiac potassium channels.Semantic proximity Read ↗

Blinded In Silico Drug Trial Reveals the Minimum Set of Ion Channels for Torsades de Pointes Risk AssessmentSemantic proximity Read ↗

Genetic and Molecular Aspects of Drug-Induced QT Interval ProlongationSemantic proximity Read ↗

Acquired long QT syndrome and torsade de pointes.Semantic proximity Read ↗

hERG potassium channels and cardiac arrhythmia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.